Effects of Testosterone Treatment in Older Men.
暂无分享,去创建一个
S. Resnick | C. Lewis | T. Gill | J. Cauley | E. Barrett-Connor | M. Pahor | J. Farrar | S. Anton | D. Cella | K. Ensrud | D. Cifelli | S. Ellenberg | E. Mohler | N. Wenger | J. Landis | B. Zeldow | S. Bhasin | A. Stephens-Shields | R. Rosen | T. Storer | J. Parsons | M. Molitch | Christina Wang | R. Swerdloff | A. Matsumoto | G. Cunningham | P. Snyder | J. Crandall | S. Basaria | S. Diem | Xiaoling Hou | Laura Fluharty | Darlene Dougar | N. K. Wenger | Denise Cifelli | Emile R. Mohler | Peter J Snyder | Thomas M Gill | John T Farrar | Raymond C Rosen | Jane A. Cauley | Cora E Lewis | Jill P. Crandall | Ronald S. Swerdloff | J. Richard Landis | Kristine E Ensrud | Glenn R. Cunningham | Alvin M. Matsumoto | Christina Wang | Susan M. Resnick | Xiaoling Hou | J. Kellogg Parsons | Susan S. Ellenberg
[1] B. Dawn,et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. , 2015, European heart journal.
[2] S. Resnick,et al. Recruitment and Screening for the Testosterone Trials. , 2015, The journals of gerontology. Series A, Biological sciences and medical sciences.
[3] A. Isidori,et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis , 2014, Expert opinion on drug safety.
[4] M. Budoff,et al. Title Erratum : The Testosterone Trials : Seven coordinated trials of testosterone treatment in elderly men , 2014 .
[5] S. Greenland,et al. Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men , 2014, PloS one.
[6] G. Grunwald,et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. , 2013, JAMA.
[7] B. Cowling,et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials , 2013, BMC Medicine.
[8] M. Pencina,et al. Sex Hormone–Binding Globulin, but Not Testosterone, Is Associated Prospectively and Independently With Incident Metabolic Syndrome in Men , 2011, Diabetes Care.
[9] A. Jette,et al. Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. , 2011, The journals of gerontology. Series A, Biological sciences and medical sciences.
[10] M. Pencina,et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. , 2011, The Journal of clinical endocrinology and metabolism.
[11] G. B. Phillips. Adverse events associated with testosterone administration. , 2010, The New England journal of medicine.
[12] S. Roberts,et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. , 2010, The Journal of clinical endocrinology and metabolism.
[13] H. Vesper,et al. Interlaboratory comparison study of serum total testoserone measurements performed by mass spectrometry methods , 2009, Steroids.
[14] A. Silman,et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. , 2008, The Journal of clinical endocrinology and metabolism.
[15] Paul J Rathouz,et al. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. , 2008, Journal of health economics.
[16] J. Bergquist,et al. High-sensitivity tandem mass spectrometry assay for serum estrone and estradiol. , 2008, American journal of clinical pathology.
[17] F. Goldstein,et al. Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. , 2007, Journal of andrology.
[18] J. Mulhall,et al. Analysis of the efficacy and safety of sildenafil citrate in the geriatric population , 2007, BJU international.
[19] Ziding Feng,et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.
[20] R. Casaburi,et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. , 2005, The Journal of clinical endocrinology and metabolism.
[21] A. Matsumoto,et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. , 2005, The Journal of clinical endocrinology and metabolism.
[22] G. Alexander,et al. A simple self-report diary for assessing psychosexual function in hypogonadal men. , 2003, Journal of andrology.
[23] D. Cella,et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. , 2002, Journal of pain and symptom management.
[24] J. Cappelleri,et al. The International Index of Erectile Function (IIEF): a state-of-the-science review , 2002, International Journal of Impotence Research.
[25] E. Metter,et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. , 2001, The Journal of clinical endocrinology and metabolism.
[26] J. Berlin,et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. , 1999, The Journal of clinical endocrinology and metabolism.
[27] D A Redelmeier,et al. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. , 1997, American journal of respiratory and critical care medicine.
[28] D. Follmann,et al. An approximate generalized linear model with random effects for informative missing data. , 1995, Biometrics.
[29] R. Little. Pattern-Mixture Models for Multivariate Incomplete Data , 1993 .
[30] Y. Benjamini,et al. More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.
[31] D. Watson,et al. Development and validation of brief measures of positive and negative affect: the PANAS scales. , 1988, Journal of personality and social psychology.
[32] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[33] D R Taves,et al. Minimization: A new method of assigning patients to treatment and control groups , 1974, Clinical pharmacology and therapeutics.
[34] D. Blazer,et al. Testosterone and aging : clinical research directions , 2004 .
[35] J. Ware. SF-36 health survey: Manual and interpretation guide , 2003 .
[36] R. Spitzer,et al. The PHQ-9: validity of a brief depression severity measure. , 2001, Journal of general internal medicine.
[37] L. Derogatis. The Derogatis Interview for Sexual Functioning (DISF/DISF-SR): an introductory report. , 1997, Journal of sex & marital therapy.